DDInter416 DDInter448
This drug is a broad spectrum antimycotic or antifungal agent. Clotrimazole's antimycotic properties were discovered in the late 1960s. Clotrimazole falls under the _imidazole_ category of _azole_ antifungals, possessing broad-spectrum antimycotic activity. It is available in various preparations, including creams, pessaries, and troche formulations (slowly dissolving tablets). As well as its antifungal activity, clotrimazole has become a drug of interest in treating several other diseases such as sickle cell disease, malaria and some cancers. The minimal side effect profile of this drug and its uncomplicated metabolic profile have led it to gain widespread acceptance for the treatment of mycotic outbreaks such as vaginal yeast infections as well as athlete's foot.
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements.
Clotrimazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Crizotinib
Clotrimazole {u} (Compound) binds {v} (Gene) CYP51A1
CYP51A1 {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Clotrimazole {u} (Compound) upregulates {v} (Gene) PHGDH
PHGDH {u} (Gene) is downregulated by {v} (Compound) Crizotinib
Clotrimazole {u} (Compound) causes {v} (Side Effect) Vomiting
Vomiting {u} (Side Effect) is caused by {v} (Compound) Crizotinib
Clotrimazole {u} (Compound) resembles {v} (Compound) Loperamide
Loperamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Crizotinib
Clotrimazole {u} (Compound) resembles {v} (Compound) Methadone
Methadone {u} may lead to a major life threatening interaction when taken with {v} Crizotinib
Clotrimazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) covaries with {v} (Gene) PTK2B
PTK2B {u} (Gene) is bound by {v} (Compound) Crizotinib
Clotrimazole {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is associated with {v} (Disease) lung cancer
lung cancer {u} (Disease) is treated by {v} (Compound) Crizotinib
Clotrimazole {u} (Compound) binds {v} (Gene) CYP51A1
CYP51A1 {u} (Gene) is regulated by {v} (Gene) SREBF2
SREBF2 {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Clotrimazole {u} (Compound) upregulates {v} (Gene) PHGDH
PHGDH {u} (Gene) interacts with {v} (Gene) MAP3K3
MAP3K3 {u} (Gene) is bound by {v} (Compound) Crizotinib
Clotrimazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Clotrimazole (Compound) binds CYP51A1 (Gene) and CYP51A1 (Gene) is upregulated by Crizotinib (Compound)
Clotrimazole (Compound) upregulates PHGDH (Gene) and PHGDH (Gene) is downregulated by Crizotinib (Compound)
Clotrimazole (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Crizotinib (Compound)
Clotrimazole (Compound) resembles Loperamide (Compound) and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Clotrimazole (Compound) resembles Methadone (Compound) and Methadone may lead to a major life threatening interaction when taken with Crizotinib
Clotrimazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) covaries with PTK2B (Gene) and PTK2B (Gene) is bound by Crizotinib (Compound)
Clotrimazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is associated with lung cancer (Disease) and lung cancer (Disease) is treated by Crizotinib (Compound)
Clotrimazole (Compound) binds CYP51A1 (Gene) and CYP51A1 (Gene) is regulated by SREBF2 (Gene) and SREBF2 (Gene) is upregulated by Crizotinib (Compound)
Clotrimazole (Compound) upregulates PHGDH (Gene) and PHGDH (Gene) interacts with MAP3K3 (Gene) and MAP3K3 (Gene) is bound by Crizotinib (Compound)